Literature DB >> 2572426

Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437.

P A Löschmann1, P N Chong, M Nomoto, P G Tepper, A S Horn, P Jenner, C D Marsden.   

Abstract

The selective dopamine D-2 receptor agonist N-0437 produced a rapid and dose-dependent reversal of motor deficits lasting 90-120 min following i.p. or oral administration of the racemate to MPTP-treated common marmosets. In contrast, topical application of (+/-)-, (+)- or (-)-N-0437 to the skin of MPTP-treated animals did not alter locomotor activity in the initial 4 h although other motor disabilities were reduced. However, 24 h following application of the racemate or the (-) enantiomer both locomotor activity and the other motor deficits induced by MPTP were improved. The increase in locomotor activity returned to basal values by 48-52 h following application of the racemate to the skin and by 72-76 h following administration of (-)-N-0437; the other motor deficits induced by MPTP were reduced for up to 72-76 h by both (+/-)- and (-)-N-0437. Application to skin of the (+) enantiomer produced no behavioural improvement or stimulation of locomotor activity. Transdermal administration of the active enantiomer of N-0437 may be of value in producing a prolonged reversal of parkinsonian motor deficits in man.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572426     DOI: 10.1016/0014-2999(89)90348-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.

Authors:  P Jenner; A C McCreary; D K A Scheller
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 2.  Parkinson's disease: pathological mechanisms and actions of piribedil.

Authors:  P Jenner
Journal:  J Neurol       Date:  1992       Impact factor: 4.849

Review 3.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

4.  Transdermal administration of the dopamine agonist N-0437 and seven ester prodrugs: comparison with oral administration in the 6-OHDA turning model.

Authors:  I den Daas; P G Tepper; H Rollema; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-12       Impact factor: 3.000

5.  The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates.

Authors:  K W Lange; P A Löschmann; E Sofic; M Burg; R Horowski; K T Kalveram; H Wachtel; P Riederer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

Review 6.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

7.  Rotigotine transdermal system: a short review.

Authors:  Sabine Bunten; Svenja Happe
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.